# Yung‐Jue Bang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yung-jue-bang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68,433 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 106 |
| i10-index | 476 |
| Last Known Institution | Seoul National University |
| OpenAlex ID | https://openalex.org/A5050684671 |
| ORCID iD | https://orcid.org/0000-0001-6000-4597 |
| Works | 1,071 |

## Researcher papers

- [Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/sunitinib-malate-for-the-treatment-of-pancreatic-neuroendocrine-tumors/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis](https://scholariq.org/papers/effect-of-crizotinib-on-overall-survival-in-patients-with-advanced-non-small/)
- [Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies](https://scholariq.org/papers/phase-i-and-pharmacokinetic-study-of-genexol-pm-a-cremophor-free-polymeric/)
- [Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib](https://scholariq.org/papers/predictive-and-prognostic-impact-of-epidermal-growth-factor-receptor-mutation-in/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib](https://scholariq.org/papers/i-met-i-amplification-identifies-a-small-and-aggressive-subgroup-of/)
- [Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/artificial-intelligence-powered-spatial-analysis-of-tumor-infiltrating/)
- [Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation](https://scholariq.org/papers/optimization-of-patient-selection-for-gefitinib-in-non-small-cell-lung-cancer-by/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Seoul National University](https://scholariq.org/institutions/seoul-national-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.